此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

SWITCH:HM3中阿哌沙班与维生素K的对比

2026年11月2日 更新者:Nir Uriel、Columbia University

SWITCH试验:一项关于阿哌沙班与维生素K拮抗剂在HeartMate 3左心室辅助装置患者中的随机对照研究

This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.

研究概览

详细说明

Heart failure is a global epidemic, and Left Ventricular Assist Devices (LVADs) - particularly the HeartMate 3 (HM3) - are increasingly used due to their survival benefit over medical therapy. Despite advances, hemocompatibility-related adverse events (HRAEs) like thrombosis and bleeding remain significant causes of morbidity and mortality.

Direct Oral Anticoagulants (DOACs) have shown superiority over warfarin in heart failure patients, with lower rates of embolic and intracranial bleeding. Reduced-dose DOACs also appear to reduce major bleeding without increasing thrombotic risk. However, data on their use in LVAD patients is limited, consisting mainly of case reports, small series, retrospective analyses, and a few small randomized clinical trials.

Some reports suggest apixaban may reduce bleeding in high-risk LVAD patients, though cases of pump thrombosis and stroke have occurred. Early studies comparing DOACs to warfarin in patients with HeartMate II (HMII), HeartWare™ HVAD™ System, and The Abbott HeartMate 3 (HM3) show no significant differences in outcomes, with a trend toward less bleeding with apixaban. Two small randomized clinical trials in HM3 patients (The DOAC LVAD Study and The DOT-HM3 Study) found similar results.

This prospective, randomized, controlled, non-inferiority trial will evaluate the safety and efficacy of apixaban versus vitamin K antagonists in HM3 patients more than 3 months post-implant.

研究类型

介入性

注册 (估计的)

460

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • New York
      • New York、New York、美国、10032
        • 招聘中
        • Columbia University Irving Medical Center
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Participants will have HeartMate3 LVAD implanted > 3 months before enrollment
  • ≥ 18 years old
  • Treated with WARFARIN SODIUM
  • Participant must provide written informed consent prior to any clinical investigation related procedure
  • In female participants of childbearing capability, not currently pregnant and on appropriate contraception

Exclusion Criteria:

  • Participation in any other clinical investigation(s) involving a Mechanical Circulatory Support (MCS) device, or interventional investigation(s) likely to confound study results or affect study outcome
  • Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
  • Known allergy to Apixaban
  • Bridge to transplant
  • Severe renal dysfunction Estimated Glomerular Filtration Rate (eGFR) <20
  • History of major bleeding event with subsequent reduction of INR goal to < 1.8
  • Apixaban dose reduction criteria (Age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL)
  • Aortic root thrombus

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Warfarin

Participants will take warfarin, dose titrated for an INR >= 1.8

Warfarin dose titrated for an International Normalized Ratio (INR) >= 1.8

其他名称:
  • 香豆素
  • 华法林钠
实验性的:Apixaban

Participants wil take apixaban 5 mg bid

Apixaban 5 mg bid (twice a day)

其他名称:
  • Eliquis

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Survival free of major hemocompatibility related adverse event
大体时间:12 months

Major Hemocompatibility Related Adverse Event: Stroke, Pump Thrombosis, major non surgical Bleeding (moderate or severe), Arterial Peripheral Thromboembolism. Rates will be compared between study groups.

12 months

次要结果测量

结果测量
措施说明
大体时间
Non-surgical Major Hemorrhagic Events
大体时间:12 months

Rates will be compared between study groups.

12 months
Non-surgical Major Thrombotic Events
大体时间:12 months

Rates will be compared between study groups.

12 months
Survival
大体时间:12 months

Rates will be compared between study groups.

12 months
Stroke Rates
大体时间:12 months

Rates will be compared between study groups.

12 months
Pump Thrombosis Rates
大体时间:12 months

Rates will be compared between study groups.

12 months
Bleeding Rates
大体时间:12 months

Rates will be compared between study groups.

12 months
Rates of listing for Heart Transplant
大体时间:12 months

Rates will be compared between study groups.

12 months

其他结果措施

结果测量
措施说明
大体时间
发生不良事件患者的阿哌沙班水平
大体时间:12个月
12个月
Patient functional status
大体时间:12 months

Association between anticoagulant regimen and New York Heart Association (NYHA) Functional Classification (FC) will be compared between groups. Scores range I through IV, with higher scores indicating worse outcome.

12 months
Patient QOL
大体时间:12 months

Kansas City Cardiomyopathy Questionnaire (KCCQ) 12 scores will be compared between groups. Scores range 1-100, with higher scores indicating better health status.

12 months
LVAD device speed
大体时间:12 months

LVAD speed (mean, SD) of LVAD will be compared between study groups. Speed ranges 4500-6000 RPM.

12 months
LVAD device flow
大体时间:12 months

LVAD flow (mean, SD) of LVAD will be compared between study groups. Flow ranges 3-6 L/min.

12 months
LVAD device pulsatility index
大体时间:12 months

LVAD pulsatility index (PI) will be compared between study groups. PI ranges 1-4 (no units).

12 months
LVAD device power
大体时间:12 months

LVAD power (mean, SD) will be compared between study groups. Power ranges 3-7 W.

12 months
Right atrial pressure
大体时间:12 months

Right atrial (RA) pressure (mean, SD) will be compared between study groups. RA ranges 0-20 mmHg.

12 months
Right ventricular systolic pressure
大体时间:12 months

Right ventricular (RV) systolic pressure (mean, SD) will be compared between study groups. RV systolic pressure ranges 0-100 mmHg.

12 months
Right ventricular diastolic pressure
大体时间:12 months

Right ventricular (RV) diastolic pressure (mean, SD) will be compared between study groups. RV diastolic pressure ranges 0-50 mmHg.

12 months
Pulmonary artery systolic pressure
大体时间:12 months

Pulmonary artery (PA) systolic pressure (mean, SD) will be compared between study groups. PA systolic pressure ranges 0-100 mmHg.

12 months
Pulmonary artery diastolic pressure
大体时间:12 months

Pulmonary artery (PA) diastolic pressure (mean, SD) will be compared between study groups. PA diastolic pressure ranges 0-50 mmHg.

12 months
Pulmonary artery mean pressure
大体时间:12 months

Pulmonary artery (PA) mean pressure (mean, SD) will be compared between study groups. PA mean pressure ranges 0-50 mmHg.

12 months
Pulmonary capillary wedge pressure
大体时间:12 months

Pulmonary capillary wedge pressure (PCWP, mean, SD) will be compared between study groups. PCWP ranges 0-50 mmHg.

12 months
Cardiac output
大体时间:12 months

Cardiac output (CO, mean, SD) will be compared between study groups. CO ranges 3-10 L/min.

12 months
Invasive hemodynamics
大体时间:12 months

Cardiac index (CI, mean, SD) will be compared between study groups. CI ranges 2.5-4 L/min/m^2.

12 months
Drive line infection rates
大体时间:12 months

Rate of drive line infections will be compared between study groups.

12 months
VAD coordinator time
大体时间:12 months

Means will be compared between study groups.

12 months
Laboratory monitoring
大体时间:12 months

A quantitative comparison of performed laboratory tests to monitor anticoagulation between groups (counts)

12 months
Days hospitalized
大体时间:12 months

Means will be compared between study groups.

12 months
Caregiver burden
大体时间:12 months

Self assessed caregiver burden will be collected using the validated The Oberst Caregiving Burden Scale (OCBS), and compared between study groups. Scores range 15-75, with higher scores indicating higher levels of caregiving burden (more time spent or greater difficulty).

12 months
Time in therapeutic range in the warfarin sodium group
大体时间:12 months

Means, as well as rates above 70%, will be compared between study groups.

12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Nir Uriel, MD、New York Presbyterian / Columbia University Medical Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月15日

初级完成 (估计的)

2029年8月1日

研究完成 (估计的)

2029年10月1日

研究注册日期

首次提交

2026年2月24日

首先提交符合 QC 标准的

2026年3月11日

首次发布 (实际的)

2026年3月13日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅